Allergy Unit, Complesso Integrato Columbus, Rome, Italy.
J Allergy Clin Immunol. 2010 Nov;126(5):994-9. doi: 10.1016/j.jaci.2010.06.052.
There have been few studies regarding the cross-reactivity and tolerability of penicillins, aztreonam, and carbapenems in large samples of subjects with cephalosporin allergy.
We sought to evaluate the possibility of using penicillins, monobactams, and carbapenems in subjects with cephalosporin allergy who especially require them.
We conducted a prospective study of 98 consecutive subjects who had 106 immediate reactions (mostly anaphylactic shock) to cephalosporins and had positive skin test results for these drugs. To assess the cross-reactivity with penicillins, monobactams, and carbapenems and the tolerability of such alternative β-lactams, all subjects underwent skin tests and serum-specific IgE assays with penicillin reagents, as well as skin tests with aztreonam, imipenem/cilastatin, and meropenem. Subjects with negative test results were challenged with meropenem, imipenem/cilastatin, aztreonam, and amoxicillin.
Positive allergologic test results to penicillins were displayed by 25 (25.5%) subjects, including 1 with positive results to all reagents tested and another with a positive result to aztreonam. Another subject had positive results to both ceftazidime and aztreonam. A reaction to cephalosporins with side-chain structures similar or identical to those of penicillins was a significant predictor of cross-reactivity because of an increased 3-fold risk of positive results on allergologic tests with penicillin determinants. Challenges with alternative β-lactams were tolerated, with the exception of 1 urticarial reaction to imipenem/cilastatin.
About 25% of subjects with cephalosporin allergy had positive results to penicillins, 3.1% to aztreonam, 2% to imipenem/cilastatin, and 1% to meropenem. In those who especially require alternative β-lactams, pretreatment skin tests are advisable because negative results indicate tolerability of the β-lactam concerned.
在有头孢菌素过敏的大量研究对象中,关于青霉素、氨曲南和碳青霉烯类药物的交叉反应性和耐受性的研究较少。
我们旨在评估在特别需要的头孢菌素过敏研究对象中使用青霉素、单酰胺类和碳青霉烯类药物的可能性。
我们进行了一项前瞻性研究,共纳入 98 例连续的研究对象,他们对头孢菌素发生了 106 次即刻反应(主要为过敏性休克),并且这些药物的皮肤试验结果为阳性。为了评估与青霉素、单酰胺类和碳青霉烯类药物的交叉反应性以及这些替代β-内酰胺类药物的耐受性,所有研究对象均进行了青霉素试剂的皮试和血清特异性 IgE 检测,以及氨曲南、亚胺培南/西司他丁和美罗培南的皮试。皮试结果阴性的研究对象进行了美罗培南、亚胺培南/西司他丁、氨曲南和阿莫西林的激发试验。
25 例(25.5%)研究对象对青霉素的过敏试验结果为阳性,其中 1 例对所有检测试剂均呈阳性,另 1 例对氨曲南呈阳性。还有 1 例对头孢他啶和氨曲南均呈阳性。头孢菌素的侧链结构与青霉素相似或相同的过敏反应是交叉反应的一个显著预测因素,因为青霉素决定簇的过敏试验结果阳性的风险增加了 3 倍。除 1 例对亚胺培南/西司他丁出现荨麻疹反应外,替代β-内酰胺类药物的激发试验均被耐受。
大约 25%的头孢菌素过敏研究对象对青霉素、3.1%对氨曲南、2%对亚胺培南/西司他丁和 1%对美罗培南的过敏试验结果为阳性。在那些特别需要替代β-内酰胺类药物的患者中,建议进行预处理皮试,因为阴性结果表明相关β-内酰胺类药物的耐受性良好。